MITHAML – Metabolic heterogeneity in acute myeloid leukaemia

Accumulating evidence indicates that metabolism is involved in the drug resistance that develops in acute myeloid leukaemia (AML). However, approaches have so far assessed metabolism as a whole, without addressing the genotypic and phenotypic heterogeneity observed in cancer. The EU-funded MITHAML project will use mass cytometry (Cytof), a single-cell technology with enormous analytical potential, to investigate the role of intratumour metabolic heterogeneity before and after treatment in vivo and in the patient. By focusing on metabolism-targeted drugs, researchers hope to find new therapeutic targets for AML. Deciphering the role of metabolism in therapeutic resistance will open new avenues for treatment with new drug combinations.

This programme will be carried out thanks to a collaboration between the laboratory of Dr K Davis (Stanford University, San Francisco, USA), very well known in the study of intratumoral heterogeneity in particular with Cytof, and the laboratory of Dr JE Sarry (CRCT Inserm, Toulouse, France), expert in the role of oncometabolism in in vivo resistance in AML. Finally, this project will be led by Dr L Stuani who will spend two years at Stanford before coming to Toulouse to establish it.

This programme is coordinated by Jean emmanuel Sarry

For more information:

Start date: 21 September 2020
End date: 20 September 2023

This research programme is part of the European call for proposals H2020-MSCA-IF-2019 (Marie Skłodowska-Curie Actions- Individual fellowship)

Pin It on Pinterest